Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Tanabe, Anaphore Enter Autoimmune R&D Pact | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Tanabe, Anaphore Enter Autoimmune R&D Pact

Tanabe Research Laboratories, Inc. (TRL) has entered into a partnership with Anaphore, Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore's Atrimer technology.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Tanabe Research Laboratories, Inc. (TRL) has entered into a partnership with Anaphore, Inc. for the research and preclinical development of novel protein therapies for autoimmune diseases based on Anaphore’s Atrimer technology.

The two companies will generate novel trivalent proteins called Atrimers that can be programmed to bind to and activate or inhibit targets of interest. The partnership will focus developing biologic therapies for such autoimmune disorders as rheumatoid arthritis, inflammatory bowel disease and psoriasis. TRL’s parent company, Mitsubishi Tanabe Pharma, will be responsible for late stage development and commercialization of lead products.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics